First successful case of platinum‐based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations. Issue 1 (20th October 2021)

• Record Type: Journal Article
• Authors: Omura, Minami; Kosaka, Takeo; Aimono, Eriko; Nakamura, Kohei; Hongo, Hiroshi; Mikami, Shuji; Nishihara, Hiroshi; Oya, Mototsugu
• Is Part Of: IJU case reports. Volume 5:Issue 1(2022)
• Page Start: 41
• Page End: 44
• Publication Date: 2021-10-20
• Subjects: BRCA2 mutation -- case report -- DNA repair -- prognosis -- treatment outcome; Urology -- Periodicals; Genitourinary organs -- Periodicals; Electronic journals; Periodicals; 616.6
• DOI: 10.1002/iju5.12383
• Languages: English
• ISSNs: 2577-171X

Abstract

Abstract : Introduction: Deoxyribonucleic acid repair gene mutations are now being studied in a variety of solid tumors, with the hope of predicting prognosis, pathogenesis, and treatment outcomes. Case presentation: We report the case of a Japanese patient with advanced castration‐resistant prostate cancer who exhibited a prominent response to platinum therapy and had coexisting BRCA2 and PTEN mutations according to retrospective multigene panel analysis. Conclusion: Through a review of clinical outcomes and genetic/pathologic profiling, the presented case provides insights into future management strategies based on the tumor genetic status.